McDonald’s McPlant burger is selling about three times more or $170 million to $215 million annualized than Piper Sandler analyst Michael Lavery initially forecasted.
Lavery initially estimated a $75 million to $100 million boost in Beyond’s US revenue due to the McPlant.
Initial McPlant sales could prove to be closer to 8 percent to 10 percent of burger sales.
For comparison, an average McDonald’s restaurant typically sells about 110 Big Macs per day.
Participating locations sold around 70 of the plant-based burgers per outlet every day in the chain’s initial small test in December.
McDonald’s began testing the product in November in eight restaurants to ascertain customer response.
Even with such a small sample size, Lavery sees interest and willingness to try the product may be greater than expected.
The fast-food chain will expand the test to about 600 restaurants in the Dallas-Fort Worth and San Francisco Bay areas on Feb. 14.
Beyond’s stock jumped nearly 3 percent in premarket trading Wednesday, while McDonald’s shares were up just 1 percent.


Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
UK Economy Grows 0.1% in Q3 2025 as Outlook Remains Fragile
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Stock Futures Rise Ahead of Holiday-Shortened Week as AI Optimism Lifts Tech
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Trump Defends Economic Record in North Carolina as Midterm Election Pressure Mounts
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Asian Stocks Rise as Wall Street Tech Rally Lifts Markets, Yen Slumps Despite BOJ Rate Hike
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Asian Markets Rise as AI Rally Caps 2025, Gold and Silver Hit Record Highs
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Oil Prices Climb in Asian Trade as Venezuela Sanctions and Middle East Tensions Fuel Risk Premium
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



